局部晚期同步性食管癌及头颈部癌患者的多模式治疗。

IF 2.8 3区 医学 Q3 ONCOLOGY
Satoshi Suzuki, Tomoya Yokota, Akifumi Notsu, Satoshi Hamauchi, Kunihiro Fushiki, Kotoe Oshima, Akihiro Ohba, Takeshi Kawakami, Takahiro Tsushima, Hirofumi Yasui, Kentaro Yamazaki, Yusuke Onozawa, Takashi Mukaigawa, Yasuhiro Tsubosa, Hirofumi Ogawa, Tsuyoshi Onoe
{"title":"局部晚期同步性食管癌及头颈部癌患者的多模式治疗。","authors":"Satoshi Suzuki, Tomoya Yokota, Akifumi Notsu, Satoshi Hamauchi, Kunihiro Fushiki, Kotoe Oshima, Akihiro Ohba, Takeshi Kawakami, Takahiro Tsushima, Hirofumi Yasui, Kentaro Yamazaki, Yusuke Onozawa, Takashi Mukaigawa, Yasuhiro Tsubosa, Hirofumi Ogawa, Tsuyoshi Onoe","doi":"10.1007/s10147-025-02816-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Head and neck squamous cell carcinoma (HNSCC) and esophageal squamous cell carcinoma (ESCC) sometimes synchronously exist. In this study, we aim to investigate survival outcome and late adverse events (AEs) in patients with locally advanced synchronous ESCC and HNSCC (LA-SEHNC).</p><p><strong>Methods: </strong>We retrospectively analyzed consecutive patients with LA-SEHNC who underwent curative-intent surgery or chemoradiotherapy (CRT) for HNSCC and ESCC between 2007 and 2024. Patients were classified into 3 groups: group A, surgery for both HNSCC and ESCC; group B, CRT for both HNSCC and ESCC; group C, CRT for either HNSCC or ESCC.</p><p><strong>Results: </strong>Forty-two patients with LA-SEHNC were identified, consisting of 7 in group A, 28 in B, and 7 in C. There were no differences in overall survival and recurrence-free survival among groups. Late AEs occurred more frequently in group B and C than A, including stenosis (51.9%/57.1% vs 0%; p = 0.04), dysphagia (59.3%/42.9% vs 0% vs.; p = 0.02), and xerostomia (74.1%/57.1% vs 14.3%; p = 0.01). The median duration of feeding tube dependency was significantly longer in group B than A (80 days vs 0 day; p < 0.01). PS ≥ 1 and irradiation at head and neck region was significantly associated with long-term feeding tube dependency (odds ratio [OR] 9.10, p = 0.005, OR 7.71e + 7, p = 0.024, respectively).</p><p><strong>Conclusion: </strong>Although no significant difference in survival was found among patients with LA-SEHNC regardless of treatment modalities, the use of radiotherapy may be associated with increased late AEs.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1764-1774"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Multimodal treatments for patients with locally advanced synchronous esophageal and head and neck cancer.\",\"authors\":\"Satoshi Suzuki, Tomoya Yokota, Akifumi Notsu, Satoshi Hamauchi, Kunihiro Fushiki, Kotoe Oshima, Akihiro Ohba, Takeshi Kawakami, Takahiro Tsushima, Hirofumi Yasui, Kentaro Yamazaki, Yusuke Onozawa, Takashi Mukaigawa, Yasuhiro Tsubosa, Hirofumi Ogawa, Tsuyoshi Onoe\",\"doi\":\"10.1007/s10147-025-02816-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Head and neck squamous cell carcinoma (HNSCC) and esophageal squamous cell carcinoma (ESCC) sometimes synchronously exist. In this study, we aim to investigate survival outcome and late adverse events (AEs) in patients with locally advanced synchronous ESCC and HNSCC (LA-SEHNC).</p><p><strong>Methods: </strong>We retrospectively analyzed consecutive patients with LA-SEHNC who underwent curative-intent surgery or chemoradiotherapy (CRT) for HNSCC and ESCC between 2007 and 2024. Patients were classified into 3 groups: group A, surgery for both HNSCC and ESCC; group B, CRT for both HNSCC and ESCC; group C, CRT for either HNSCC or ESCC.</p><p><strong>Results: </strong>Forty-two patients with LA-SEHNC were identified, consisting of 7 in group A, 28 in B, and 7 in C. There were no differences in overall survival and recurrence-free survival among groups. Late AEs occurred more frequently in group B and C than A, including stenosis (51.9%/57.1% vs 0%; p = 0.04), dysphagia (59.3%/42.9% vs 0% vs.; p = 0.02), and xerostomia (74.1%/57.1% vs 14.3%; p = 0.01). The median duration of feeding tube dependency was significantly longer in group B than A (80 days vs 0 day; p < 0.01). PS ≥ 1 and irradiation at head and neck region was significantly associated with long-term feeding tube dependency (odds ratio [OR] 9.10, p = 0.005, OR 7.71e + 7, p = 0.024, respectively).</p><p><strong>Conclusion: </strong>Although no significant difference in survival was found among patients with LA-SEHNC regardless of treatment modalities, the use of radiotherapy may be associated with increased late AEs.</p>\",\"PeriodicalId\":13869,\"journal\":{\"name\":\"International Journal of Clinical Oncology\",\"volume\":\" \",\"pages\":\"1764-1774\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10147-025-02816-z\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-025-02816-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:头颈部鳞状细胞癌(HNSCC)和食管鳞状细胞癌(ESCC)有时同时存在。在这项研究中,我们的目的是调查局部晚期同步ESCC和HNSCC (LA-SEHNC)患者的生存结局和晚期不良事件(ae)。方法:我们回顾性分析了2007年至2024年间连续接受治疗目的手术或放化疗(CRT)治疗的LA-SEHNC和ESCC患者。患者分为3组:A组,同时手术治疗HNSCC和ESCC;B组HNSCC和ESCC均为CRT;C组:HNSCC或ESCC的CRT。结果:共发现LA-SEHNC患者42例,其中A组7例,B组28例,c组7例。各组总生存期和无复发生存期无差异。B组和C组晚期ae发生率高于A组,包括狭窄(51.9%/57.1% vs 0%);P = 0.04),吞咽困难(59.3%/42.9% vs 0%;P = 0.02),口干症(74.1%/57.1% vs 14.3%;p = 0.01)。B组饲管依赖时间中位数明显长于A组(80天vs 0天;结论:尽管不论何种治疗方式,LA-SEHNC患者的生存率没有显著差异,但放疗的使用可能与晚期ae的增加有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Multimodal treatments for patients with locally advanced synchronous esophageal and head and neck cancer.

Background: Head and neck squamous cell carcinoma (HNSCC) and esophageal squamous cell carcinoma (ESCC) sometimes synchronously exist. In this study, we aim to investigate survival outcome and late adverse events (AEs) in patients with locally advanced synchronous ESCC and HNSCC (LA-SEHNC).

Methods: We retrospectively analyzed consecutive patients with LA-SEHNC who underwent curative-intent surgery or chemoradiotherapy (CRT) for HNSCC and ESCC between 2007 and 2024. Patients were classified into 3 groups: group A, surgery for both HNSCC and ESCC; group B, CRT for both HNSCC and ESCC; group C, CRT for either HNSCC or ESCC.

Results: Forty-two patients with LA-SEHNC were identified, consisting of 7 in group A, 28 in B, and 7 in C. There were no differences in overall survival and recurrence-free survival among groups. Late AEs occurred more frequently in group B and C than A, including stenosis (51.9%/57.1% vs 0%; p = 0.04), dysphagia (59.3%/42.9% vs 0% vs.; p = 0.02), and xerostomia (74.1%/57.1% vs 14.3%; p = 0.01). The median duration of feeding tube dependency was significantly longer in group B than A (80 days vs 0 day; p < 0.01). PS ≥ 1 and irradiation at head and neck region was significantly associated with long-term feeding tube dependency (odds ratio [OR] 9.10, p = 0.005, OR 7.71e + 7, p = 0.024, respectively).

Conclusion: Although no significant difference in survival was found among patients with LA-SEHNC regardless of treatment modalities, the use of radiotherapy may be associated with increased late AEs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.80
自引率
3.00%
发文量
175
审稿时长
2 months
期刊介绍: The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信